K-Nearest Neighbor Based Missing Data Estimation Algorithm in Wireless Sensor Networks

In wireless sensor networks, the missing of sensor data is inevitable due to the inherent characteristic of wireless sensor networks, and it causes many difficulties in various applications. To solve the problem, the missing data should be estimated as accurately as possible. In this paper, a k-nearest neighbor based missing data estimation algorithm is proposed based on the temporal and spatial correlation of sensor data. It adopts the linear regression model to describe the spatial correlation of sensor data among different sensor nodes, and utilizes the data information of multiple neighbor nodes to estimate the missing data jointly rather than independently, so that a stable and reliable estimation performance can be achieved. Experimental results on two real-world datasets show that the proposed algorithm can estimate the missing data accurately.

TCR-mimic antibody-drug conjugates targeting intracellular tumor-specific mutant antigen KRAS G12V mutation

Limited clinical application of antibody-drug conjugates(ADCs)targeting tumor associated antigens(TAAs)is usually caused by on-target off-tumor side effect.Tumor-specific mutant antigens(TSMAs)only expressed in tumor cells which are ideal targets for ADCs.In addition,intracellular somatic mutant proteins can be presented on the cell surface by human leukocyte antigen class I(HLA I)molecules forming tumor-specific peptide/HLA I complexes.KRAS G12 V mutation frequently occurred in varied cancer and was verified as a promising target for cancer therapy.In this study,we generated two TCR-mimic antibodydrug conjugates(TCRm-ADCs),2E8-MMAE and 2 A5-MMAE,targeting KRAS G12 V/HLAA*0201 complex,which mediated specific antitumor activity in vitro and in vivo without obvious toxicity.Our findings are the first time validate the strategy of TCRm-ADCs targeting intracellular TSMAs,which improves the safety of antibody-based drugs and provides novel strategy for precision medicine in cancer therapy.

A multivalent biparatopic EGFR-targeting nanobody drug conjugate displays potent anticancer activity in solid tumor models

Dear Editor,The epidermal growth factor receptor(EGFR),one member of the ErbB family of receptor tyrosine kinases,has been implicated in various epithelial malignancies.As a clinically validated target,both small-molecule tyrosine kinase inhibitors and antibody-based drugs have been approved by regulatory agencies.Anti-EGFR antibodyci rug conjugates(ADCs)could kill target tumor cells irrespective of EGFR signaling.However,cancer patients treated with EGFR-targeted antibody therapy eventually develop acquired epitope substitutions such as S492R,G465R,G465E,and 1491M.

Emerging new therapeutic antibody derivatives for cancer treatment

Monoclonal antibodies constitute a promising class of targeted anticancer agents that enhance natural immune system functions to suppress cancer cell activity and eliminate cancer cells.The successful application of IgG monoclonal antibodies has inspired the development of various types of therapeutic antibodies,such as antibody fragments,bispecific antibodies,and antibody derivatives(e.g.,antibody-drug conjugates and immunocytokines).